Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd.
Clinical trials sponsored by Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug 608 aims to ease back pain in ankylosing spondylitis Results expected Jan 2027 (estimated)
- New asthma drug shows promise in late-stage trial Results expected Feb 2027 (estimated)
- New drug 610 aims to tame severe asthma attacks Results expected Feb 2027 (estimated)
- New antibody injection could stop gout flares while lowering uric acid Results expected Aug 2027 (estimated)
- New injection aims to tame tough eczema Results expected Aug 2027 (estimated)
-
New asthma drug shows promise in late-stage trial
Disease control OngoingThis study tests a new antibody drug (called 610) for adults with severe asthma that is not well controlled by standard inhalers. About 225 participants will receive either the drug or a placebo to see if it improves lung function and reduces asthma attacks over 52 weeks. The dru…
Phase 2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for stuffy noses: experimental drug targets nasal polyps
Disease control OngoingThis study tests an investigational drug called 611 in 243 adults with chronic sinusitis and nasal polyps that haven't been well-controlled by other treatments. The goal is to see if 611 can shrink polyps and ease nasal congestion over 24 weeks. Participants receive either the dr…
Phase 3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC